Death-Associated Protein Kinase (Nonspecified Subtype): A Promising Drug Target and Biomarker

Target Name: Death-associated protein kinase

NCBI ID: P12098

Death-associated protein kinase

Other Name(s): DAPK

Death-Associated Protein Kinase (Nonspecified Subtype): A Promising Drug Target and Biomarker

Death-associated protein kinase (DAPK) is a protein that plays a crucial role in the regulation of cell survival and apoptosis. The nonspecific subtype of DAPK (DAPK(NS)) is a protein that is expressed in various cell types and is involved in the regulation of cell survival, apoptosis, and inflammation. DAPK(NS) has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DAPK(NS) function and mechanism

DAPK(NS) is a protein that is involved in the regulation of several cellular processes, including cell survival, apoptosis, and inflammation. DAPK(NS) functions as a kinase that is involved in the regulation of several protein substrates. DAPK(NS) has been shown to play a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death.

DAPK(NS) has been shown to regulate the apoptosis-related protein Bcl-2. Bcl-2 is a protein that is involved in the regulation of apoptosis, and DAPK(NS) has been shown to inhibit the activity of Bcl-2, which can lead to the regulation of cell apoptosis.

DAPK(NS) has also been shown to regulate the expression of several genes that are involved in cell apoptosis. For example, DAPK(NS) has been shown to regulate the expression of genes that are involved in the production of pro-inflammatory cytokines, such as TNF-伪 and IL-12. Pro-inflammatory cytokines play a role in the regulation of inflammation and have been implicated in the development of several diseases, including cancer and neurodegenerative diseases.

DAPK(NS) involvement in diseases

DAPK(NS) has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DAPK(NS) has been shown to be involved in the regulation of cancer cell survival. Several studies have shown that DAPK(NS) is involved in the regulation of cancer cell apoptosis, which is the process by which cancer cells undergo programmed cell death. These studies have led to the hypothesis that DAPK(NS) may be a useful drug target for cancer treatment.

DAPK(NS) has also been shown to be involved in the regulation of neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and are often associated with the development of progressive neurodegeneration. DAPK(NS) has been shown to play a role in the regulation of neurodegenerative diseases by regulating the apoptosis-related protein Bcl-2.

DAPK(NS) has also been shown to be involved in the regulation of autoimmune disorders. Autoimmune disorders, such as rheumatoid arthritis and lupus, are characterized by the immune system attacking the body's own tissues. DAPK(NS) has been shown to play a role in the regulation of autoimmune disorders by regulating the production of pro-inflammatory cytokines.

DAPK(NS) potential therapeutic applications

DAPK(NS) has the potential to be a useful drug target and biomarker for the treatment of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DAPK(NS) has been shown to be involved in the regulation of cancer cell

Protein Name: Death-associated Protein Kinase (nonspecified Subtype)

The "Death-associated protein kinase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Death-associated protein kinase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets